Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications

What is the association between tirzepatide and weight reduction among patients with overweight or obesity who initiated concomitant weight-inducing medications?In this post hoc analysis of participants in the SURMOUNT-1, -3, and -4 trials receiving at least 1 concomitant weight-inducing medication (17.3%-20.0%), tirzepatide treatment was associated with comparable weight loss to the primary study results.This study suggests that clinically meaningful weight reduction with tirzepatide may be able to be achieved among people with overweight or obesity who require treatment with weight-inducing medications.

Corresponding Author: Donna Mojdami, MD, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (mojdami_donna@lilly.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.